Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 2/20 | 0.32 |
| ▸ | ADH1C | P00326 | 2/20 | 0.32 |
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH7 | P40394 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20003036 | 0.83 | ACE2 (0.33) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL20309281 | 0.79 | — | — | |
| SCHEMBL22845127 | 0.79 | — | — | |
| SCHEMBL24447300 | 0.79 | TSHR (0.34) | TSHRLMNA | |
| SCHEMBL14401888 | 0.78 | — | — | |
| SCHEMBL24447215 | 0.76 | OPRM1 (0.37) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5932832 | 0.75 | TSHR (0.46) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL1485618 | 0.74 | — | — | |
| SCHEMBL21388583 | 0.74 | — | — | |
| SCHEMBL17808443 | 0.73 | EPHX1 (0.46) | TSHREPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-20210047315-A1 | CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| WO-2019186497-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | WO | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047315-A1 | CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | DRD3, DRD2, DRD1 | TSHR 29/4885ADH1B 1141/4885ADH1C 663/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | TSHR 80/4885ADH1B 1750/4885ADH1C 913/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | TSHR 80/4885ADH1B 1750/4885ADH1C 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.